STOCK TITAN

Shattuck Labs Inc - STTK STOCK NEWS

Welcome to our dedicated news page for Shattuck Labs (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Shattuck Labs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Shattuck Labs's position in the market.

Rhea-AI Summary
Shattuck Labs, Inc. (STTK) appoints Dr. Clay Siegall and Dr. Kate Sasser to its Board of Directors. Both bring valuable industry experience to lead late-stage clinical development of SL-172154, a promising new therapy for cancer and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
management
-
Rhea-AI Summary
Shattuck Labs, Inc. announced positive topline data from ongoing clinical trials of SL-172154 in combination with azacitidine in frontline HR-MDS and TP53m AML patients. The company completed enrollment in Phase 1B dose-expansion cohorts and entered into a collaboration with Ono Pharmaceutical Co. The financial results for Q4 2023 showed $130.6 million in cash and cash equivalents, with reduced R&D and G&A expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.54%
Tags
earnings
-
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) announced participation in investor conferences to discuss the development of bi-functional fusion proteins for cancer and autoimmune disease treatment. Key conferences include TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference 2024, and Citi's Biotech C-Suite Fireside Chat Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
none
Rhea-AI Summary
Ono Pharmaceutical Co., Ltd. announced a drug discovery collaboration and option agreement with Shattuck Labs, Inc. to develop bifunctional fusion proteins for autoimmune and inflammatory diseases. Shattuck will generate fusion proteins for targets using its technology, with Ono having the option to develop and commercialize resulting drug candidates worldwide. The agreement includes research funding, an upfront payment, milestones, and royalties up to $227 million. Pre-clinical studies showed promising immunoregulatory effects of the fusion proteins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
-
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) collaborates with Ono Pharmaceutical Co., Ltd. to develop novel bifunctional fusion proteins for autoimmune and inflammatory diseases. The agreement includes significant financial incentives up to $227 million, showcasing the potential of this partnership in advancing biologic medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
none
-
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) provided a corporate update, highlighting key milestones anticipated in 2024. The company delivered key safety and efficacy data in 2023 and strengthened financial resources. Preliminary results demonstrate initial anti-tumor activity and an acceptable safety profile for SL-172154, with opportunities in HR-MDS, AML, and ovarian cancer. Shattuck also announced a $50 million registered offering of common stock and concurrent private placement of pre-funded warrants. The company expects its cash and investments to be sufficient to fund operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.94%
Tags
none
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) to present corporate update at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.14%
Tags
none
-
Rhea-AI Summary
Shattuck Labs, Inc. (NASDAQ: STTK) announced the pricing of a registered offering of 4,651,163 shares of common stock at $6.45 per share, as well as a private placement of pre-funded warrants to purchase 3,100,823 shares of common stock at a purchase price of $6.4499 per pre-funded warrant, with expected gross proceeds of approximately $50 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
Shattuck Labs, Inc. (STTK) announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients, showing a 79% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations, and a 27% initial CR with incomplete hematologic recovery (CRi) in frontline TP53m AML patients. SL-172154 demonstrated an acceptable safety and tolerability profile as a monotherapy and in combination with azacitidine. The company will host a conference call and webcast to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
130.33%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.56%
Tags
conferences clinical trial
Shattuck Labs Inc

Nasdaq:STTK

STTK Rankings

STTK Stock Data

426.32M
30.26M
13.26%
59.87%
2.98%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About STTK

shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. compounds derived from shattuck’s proprietary agonist redirected checkpoint, arc®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. the company’s lead wholly owned program, sl-172154 (sirpα-fc-cd40l), which is designed to block the cd47 immune checkpoint and simultaneously agonize the cd40 pathway, is being evaluated in a phase 1 trial. a second compound, sl-279252 (pd1-fc-ox40l), is being evaluated in a phase 1 trial in collaboration with takeda pharmaceuticals. additionally, the company is advancing a proprietary gamma delta t cell engager, gadlen™, platform, which is designed to bridge gamma delta t cells to tumor antigens for the treatment of patients with cancer. shattuck has offices in both austin, tex